Astellas has invested heavily in novel technologies that are not necessarily the most successful or popular in the industry.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

Some of the market’s biggest winners start off as the smallest players. While trillion-dollar tech giants like the ...

Fulcrum Therapeutics' promising treatment for Sickle Cell Disease and their strong financial position, despite setbacks.

Announcement coincides with WORLDSymposium™ presentation highlighting knockdown of GYS1 mRNA and protein in muscle, as well as favorable safety and ...

Cytokinetics , Inc. (NASDAQ:CYTK), with a market capitalization of $5.65 billion, is approaching a pivotal moment in its journey to become a leading player in the cardiovascular therapeutics market.

IV edaravone-treated patient had longer disease progression milestone-free ... that results in cell neuron death and progressive muscular weakness. The IV formulation of edaravone was approved ...

Schwartz, MD, of Hattiesburg Clinic Memory Center, urges physicians about Alzheimer’s disease. “Don’t wait,” is the ... or even prevent progression to later stages. There's a robust pipeline of new ...

Positive interim data was reported from the ENERGY 1 trial and Expanded Access Program that featured a total of 5 infants and 1 child.

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker ... the Tokyo-based company is focused neuromuscular disorders, Chief Medical Officer Tadaaki Taniguchi ...

French pharma company Genfit has reached a deal to buy Versantis of Switzerland, adding three development-stage drug candidates ... pledge to build a pipeline in rare liver diseases behind ...